or
Remember me
Back
“We view the results as positive for the shares given improvement in margins despite the lower activity levels,” Acumen Capital analyst Jim Byrne said in a note. “The company has been adding accretive acquisitions to its U.S. operations in 2026, and we anticipate solid results in the next few quarters.
He maintained his “buy” rating and $9 target.
“We believe the shares are attractive at ~14% free cash flow yield and just 3.9x 2026 EV/EBITDAS,” he wrote.
Receive investor kits and email updates from Stockhouse and directly from these companies.
